Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Blog posts

Fluid Overload – the overlooked challenge in heart failure
Ian Crosbie – 22 October 2020

Read the post

Serving the needs of NASH patients
Ian Crosbie, 12 November 2020

Read the post

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES